TNF-alpha: an inflammatory cytokine that is hard to measure well

Tumour necrosis factor-alpha (TNF-alpha) is a cytokine made mainly by immune cells called macrophages, and also by fat tissue. It drives fever, inflammation and the acute-phase response, and it is the target of anti-TNF drugs such as infliximab and adalimumab used in rheumatoid arthritis, Crohn's disease, psoriasis and related conditions. In blood it is reported in pg/mL. Its levels in healthy people are very low and it is cleared from the blood quickly, which is part of why measuring it is difficult.

The ranges

The same blood can give different numbers on different platforms, and Cleveland Clinic lists an upper limit of 7.2 pg/mL for its serum assay, more than twice these. That is the main practical fact about this test: a value only means something against the range printed by the lab that ran it, and only in a series from the same lab. There is no guideline "optimal" TNF-alpha.

What raises and lowers it

• Raises: infection and sepsis, active autoimmune and inflammatory disease, excess visceral fat, chronic heart and kidney disease, and ageing.
• Lowers: anti-TNF drugs (though some assays then measure drug-bound TNF in confusing ways), treatment of the underlying disease, and weight loss.
• Artefact: delays in processing, clotting and the wrong tube can change the reading, which is why Mayo specifies a chilled plasma sample frozen within two hours.

What it predicts

The 2014 cytokine meta-analysis in the European Heart Journal pooled up to 29 prospective studies. Per one standard deviation higher log TNF-alpha, the adjusted relative risk of non-fatal heart attack or coronary death was 1.17 (95% CI 1.09 to 1.25). That was weaker than IL-6 (1.25) in the same analysis, and the authors said causality needed more research. TNF-alpha is not part of any cardiovascular risk score.

Where TNF-alpha clearly matters is in inflammatory disease, where blocking it changes the course of conditions such as rheumatoid arthritis. Even there, doctors monitor the disease with symptoms, CRP and ESR, not with TNF-alpha levels.

On GLP-1 drugs and weight loss

The pivotal semaglutide and tirzepatide trials do not report TNF-alpha as an outcome. Fat tissue is one source of it, and weight loss lowers CRP, so a fall is plausible, but there is no trial number to give. If you test it during treatment, compare only against your own baseline from the same lab, drawn under the same conditions.

How to test

• Ask the lab about handling before the draw: tube type, chilling and time to freezing.
• Be well, with no infection, vaccination or injury in the previous two weeks, and no hard training for 48 hours.
• Same lab, same assay, every time.
• Read it with IL-6 and hs-CRP, which have better-established ranges and more outcome data.

Is it worth testing at all? For most people tracking general health, hs-CRP answers the same question with a standardised assay, a guideline framework and trial data behind it. TNF-alpha earns its place when a clinician is looking at a specific inflammatory condition, or when you already have a baseline series from one lab and want to keep it going. A single TNF-alpha result with no baseline and no clinical question is hard to interpret, and the honest reading of most values is "within this lab's range" or "repeat it".

Tracking it in Peptide AI

In Peptide AI, TNF-alpha sits in the inflammatory panel. The app reads it from a lab PDF or manual entry, scores the panel from 0 to 100 alongside an overall grade, flags values that warrant prompt physician consultation, and plots each result against your dose timeline. Log the draw date, whether you fasted, and anything unusual in the days before, such as illness, a hard session or a dose step, so the next result is compared like with like. Bloodwork tracking shows the series next to the dose log, weight and side effects, and the panels page lists every marker the app groups. More markers are in the bloodwork guides.